David Kieta, CRNP

David Kieta practices at Bright Horizons Adult Partial Hospitalization in Uniontown, Pennsylvania.

David Kieta's NPI, 1194062109, was assigned on January 10, 2013. David Kieta holds Pennsylvania license SP012577.

David Kieta's primary practice is Bright Horizons Adult Partial Hospitalization, at 100 New Salem Road, Uniontown, PA 15401. The practice phone is (724) 437-0729. David Kieta also practices at Chestnut Ridge Counseling Services Inc, 188 New Salem Rd, Uniontown, PA 15401.

David Kieta's primary practice is Bright Horizons Adult Partial Hospitalization in Uniontown, Pennsylvania. David Kieta is also affiliated with WVU Medicine Uniontown Hospital. The medical group on file is Chestnut Ridge Counseling Services. Dmand AI also links David Kieta to 1 more hospital, 1 behavioral health center and 1 group practice or clinic, each named with a free account. David Kieta's employer is on file too: a behavioral health center.

Dmand AI tracks the electronic health record (EHR) system at each site where David Kieta practices, 5 sites in all. Vendor and product names are available with a free account.

Family is David Kieta's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. David Kieta is licensed in Pennsylvania.

CMS counts 116 Medicare patients who saw David Kieta in 2024. The largest group is under 65, with 61 patients. 69% of them have anxiety, and 68% have high cholesterol. 78% are also on Medicaid. Their average risk score is 1.42, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts David Kieta's median patient age at 55, with 52% women.

In 2024, David Kieta wrote 11,232 Medicare Part D claims for 370 patients. 92% of them were for generic drugs.

David Kieta accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists David Kieta as offering telehealth.

CMS Open Payments shows 2 general payments to David Kieta from 2 drug and device companies in 2025. Education make up the largest share, 58% of the total. Bristol-Myers Squibb Company paid the most, $27.